Khalighi Mehraneh, Yazici Nancy M, Cornia Paul B
Veterans Affairs Puget Sound Health Care System, Seattle, Washington.
University of Washington, Seattle.
Fed Pract. 2022 Nov;39(Suppl 5):S28-S34a. doi: 10.12788/fp.0335. Epub 2022 Nov 14.
Guidelines offer varying recommendations for preoperative long-acting basal insulin dosing, despite mounting evidence of the advantages of maintaining perioperative glucose levels between 80 and 180 mg/dL.
We iteratively adjusted health care practitioner (HCP) instructions to intensify insulin dosing on the evening before surgery for 195 consecutive patients with diabetes mellitus treated with long-acting basal insulin with an evening dosage. Baseline data was collected in phase 1. In phase 2, the preoperative insulin dose on the evening before surgery was increased for patients with hemoglobin A (HbA) > 8%; in phase 3, it was increased for patients with HbA ≤ 8% while sustaining the phase 2 change. Increased preoperative insulin doses did not change the rates of day of surgery (DOS) hyperglycemia or hypoglycemia. Overall, HCP adherence to the modified protocols was high (89%). A decline in HCP adherence after phase 2 protocol change was associated with a transient increase in DOS hyperglycemia. Patient adherence to preoperative medication instructions was high (86%) and was not affected by protocol changes.
Preoperative insulin intensification the evening before surgery did not change rates of DOS hyperglycemia or hypoglycemia. HCP adherence decreased transiently, which briefly increased DOS hyperglycemia rates in some patients. Perioperative hyperglycemia, defined as blood glucose levels ≥ 180 mg/dL in the immediate pre- and postoperative period, is associated with increased postoperative morbidity, including infections, preoperative interventions, and in-hospital mortality.1-3 Despite being identified as a barrier to optimal perioperative glycemic control, limited evidence is available on patient or health care practitioner (HCP) adherence to preoperative insulin protocols.4-6.
尽管越来越多的证据表明围手术期血糖水平维持在80至180mg/dL之间具有优势,但指南对于术前长效基础胰岛素剂量的推荐各不相同。
我们对195例接受长效基础胰岛素晚间剂量治疗的糖尿病患者,反复调整医护人员(HCP)的指导意见,以加强术前一晚的胰岛素剂量。在第1阶段收集基线数据。在第2阶段,对于血红蛋白A(HbA)>8%的患者,术前一晚的胰岛素剂量增加;在第3阶段,对于HbA≤8%的患者增加剂量,同时维持第2阶段的改变。术前胰岛素剂量增加并未改变手术日(DOS)高血糖或低血糖的发生率。总体而言,HCP对修改后方案的依从性较高(89%)。第2阶段方案改变后HCP依从性的下降与DOS高血糖的短暂增加相关。患者对术前用药指导的依从性较高(86%),且不受方案改变的影响。
术前一晚强化胰岛素治疗并未改变DOS高血糖或低血糖的发生率。HCP依从性短暂下降,这在一些患者中短暂增加了DOS高血糖发生率。围手术期高血糖定义为术前即刻和术后血糖水平≥180mg/dL,与术后发病率增加相关,包括感染、术前干预和住院死亡率。1-3尽管被认为是围手术期最佳血糖控制的障碍,但关于患者或医护人员(HCP)对术前胰岛素方案的依从性的证据有限。4-6